Login to Your Account



Myogen Sinks On Bad News From Enoximone's Phase III

By Randall Osborne


Tuesday, June 28, 2005
Three months after Myogen Inc.'s lead drug candidate for heart failure, enoximone, missed statistical significance in the primary endpoint of a Phase III trial - an event the company blamed on unexpected improvements in patients given placebo - the compound has failed in top-line results from two more Phase III studies. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription